Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Smolen

Showing results (1021-1030 of 1,467) with videos related to

Pageof 147
Sort By:
JAMA|March 5, 2004
Soluble RANKL and risk of nontraumatic fractureGeorg Schett, Stefan Kiechl, Kurt Redlich, et al.
Rheumatology (Oxford, England)|July 24, 2020
Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trialJosef S Smolen, Stanley B Cohen, Hans-Peter Tony, et al.
American Journal of Clinical and Experimental Urology|September 23, 2024
Steps toward identification of a novel cue-positive overactive bladder phenotype in women with high-bother urinary urgencySarah T Kodama, Ria Khandpur, Jared Dunlap, et al.
Annals of the Rheumatic Diseases|April 12, 2006
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparisonB Combe, C Codreanu, U Fiocco, et al.
Annals of the Rheumatic Diseases|March 25, 2000
Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosusK Redlich, S Ziegler, H P Kiener, et al.
Lancet (London, England)|October 22, 1994
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritisM J Elliott, R N Maini, M Feldmann, et al.
Arthritis and Rheumatism|April 9, 2005
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy studyJ S Smolen, C Han, M Bala, et al.
Rheumatology and Therapy|May 16, 2018
Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc AnalysesVibeke Strand, Arthur Kavanaugh, Alan J Kivitz, et al.
Psychoneuroendocrinology|January 17, 2016
Initial evidence for the link between activities and health: Associations between a balance of activities, functioning and serum levels of cytokines and C-reactive proteinMona Dür, Günter Steiner, Michaela Alexandra Stoffer, et al.
Frontiers in Immunology|June 14, 2021
Plasma Adenosine Deaminase (ADA)-1 and -2 Demonstrate Robust Ontogeny Across the First Four Months of Human LifeOludare A Odumade, Alec L Plotkin, Jensen Pak, et al.
Pageof 147

Showing results (1021-1030 of 1,467) with videos related to

Sort By:
Pageof 147
JAMA|March 5, 2004
Soluble RANKL and risk of nontraumatic fractureGeorg Schett, Stefan Kiechl, Kurt Redlich, et al.
Rheumatology (Oxford, England)|July 24, 2020
Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trialJosef S Smolen, Stanley B Cohen, Hans-Peter Tony, et al.
American Journal of Clinical and Experimental Urology|September 23, 2024
Steps toward identification of a novel cue-positive overactive bladder phenotype in women with high-bother urinary urgencySarah T Kodama, Ria Khandpur, Jared Dunlap, et al.
Annals of the Rheumatic Diseases|April 12, 2006
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparisonB Combe, C Codreanu, U Fiocco, et al.
Annals of the Rheumatic Diseases|March 25, 2000
Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosusK Redlich, S Ziegler, H P Kiener, et al.
Lancet (London, England)|October 22, 1994
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritisM J Elliott, R N Maini, M Feldmann, et al.
Arthritis and Rheumatism|April 9, 2005
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy studyJ S Smolen, C Han, M Bala, et al.
Rheumatology and Therapy|May 16, 2018
Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc AnalysesVibeke Strand, Arthur Kavanaugh, Alan J Kivitz, et al.
Psychoneuroendocrinology|January 17, 2016
Initial evidence for the link between activities and health: Associations between a balance of activities, functioning and serum levels of cytokines and C-reactive proteinMona Dür, Günter Steiner, Michaela Alexandra Stoffer, et al.
Frontiers in Immunology|June 14, 2021
Plasma Adenosine Deaminase (ADA)-1 and -2 Demonstrate Robust Ontogeny Across the First Four Months of Human LifeOludare A Odumade, Alec L Plotkin, Jensen Pak, et al.
Pageof 147